Epilepsy and Seizure Disorders trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Epilepsy and Seizure Disorders. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month3 studies across 2 companies, in the next 180 days.
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| XENE | Xenon Pharmaceuticals Inc. | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)NCT05716100Median percent change (MPC) in focal seizure frequency from baseline to DBP for XEN1101 versus placebo. | Phase 3 | Recruiting | Oct 2026 | ≤ 72 d | 2026-05-14 |
December 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PRAX | Praxis Precision Medicines | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyNCT07019922To assess the efficacy of elsunersen on seizure frequency in participants with early-onset SCN2A DEE | Phase 3 | Recruiting | Dec 2026 | ≤ 133 d | 2026-08-03 |
January 2027 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| PRAX | Praxis Precision Medicines | Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresNCT07505004To evaluate the efficacy of vormatrigine compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs | Phase 3 | Active, not recruiting | Jan 2027 | ≤ 164 d | 2026-08-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Epilepsy and Seizure Disorders
most recently updated first156 studies match. Showing the first 100 of 156 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RAPP | Rapport Therapeutics Inc. | $2.4B | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1NCT07563881Median Percent Change in Seizure Frequency | Phase 3 | Recruiting | Drug: RAP-219, RAP-219 · Other: Placebo | Focal Seizure, Epilepsy, Focal Epilepsy | 333 | 2026-06-05 | Jul 2029 | ≤ 1,076 d | 2026-08-13 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset SeizuresNCT07233239Percent change in countable focal seizure frequency compared to baseline | Phase 1 | Recruiting | Drug: CBD-OS | Focal Seizures | 100 | 2025-11-26 | 2027-11-29 | in 466 d | 2026-08-11 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic SeizuresNCT05667142Median percent change (MPC) in monthly (28 days) PGTCS frequency | Phase 3 | Recruiting | Drug: XEN1101, Placebo | Primary Generalized Tonic-Clonic Seizures | 160 | 2023-02-14 | Apr 2027 | ≤ 253 d | 2026-08-10 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | An Open-label Study of XEN1101 in EpilepsyNCT05718817The adverse events | Phase 3 | Enrolling by invitation | Drug: XEN1101 | Focal Epilepsy, Tonic-Clonic Seizures | 880 | 2023-04-25 | Apr 2033 | ≤ 2,445 d | 2026-08-10 |
| PRAX | Praxis Precision Medicines | $10.3B | Double-blind, Randomized Trial of PRAX-628 in Adults With Focal Seizures to Evaluate Efficacy and Safety (POWER1)NCT06999902To evaluate the efficacy of PRAX-628 compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs | Phase 2/3 | Completed | Drug: 20mg/day PRAX-628 for 6 weeks then 30mg/day PRAX-628 for remaining 6 weeks, Placebo | Focal Seizure | 255 | 2024-12-11 | 2026-05-14actual | — | 2026-08-10 |
| RAPP | Rapport Therapeutics Inc. | $2.4B | Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal SeizuresNCT07594119Median Percent Change in Seizure Frequency | Phase 3 | Recruiting | Drug: RAP-219, RAP-219 · Other: Placebo | Focal Seizure, Epilepsy, Focal Epilepsy | 312 | Aug 2026 | Jul 2029 | ≤ 1,076 d | 2026-08-05 |
| PRAX | Praxis Precision Medicines | $10.3B | A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic EncephalopathyNCT05737784Number of participants with treatment-emergent adverse events (Preliminary Safety, Dose Escalation) | Phase 1/2 | Active, not recruiting | Drug: PRAX-222 - Initial Dose, PRAX-222 - Initial Ascending Doses, PRAX-222 - Optional Ascending Doses, PRAX-222 - Fixed Doses · Procedure: Placebo | SCN2A-DEE, Epilepsy | 60 | 2023-04-13 | 2026-04-01actual | — | 2026-08-03 |
| PRAX | Praxis Precision Medicines | $10.3B | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and SafetyNCT07019922To assess the efficacy of elsunersen on seizure frequency in participants with early-onset SCN2A DEE | Phase 3 | Recruiting | Drug: 1mg elsunersen, 0.5mg elsunersen | Epileptic Encephalopathy, SCN2A Encephalopathy | 40 | 2025-08-13 | Dec 2026 | ≤ 133 d | 2026-08-03 |
| PRAX | Praxis Precision Medicines | $10.3B | Clinical Trial of Vormatrigine in Adult Patients With EpilepsyNCT07287163To assess the safety and tolerability of vormatrigine in adults with focal or primary generalized tonic-clonic seizures | Phase 3 | Enrolling by invitation | Drug: vormatrogine | Epilepsy, Tonic-Clonic, Focal Seizure, Primary Generalized Seizure | 700 | 2025-10-27 | 2028-05-31 | in 650 d | 2026-08-03 |
| PRAX | Praxis Precision Medicines | $10.3B | Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal SeizuresNCT07505004To evaluate the efficacy of vormatrigine compared to placebo on focal seizure frequency in adults currently taking 1 to 3 ASMs | Phase 3 | Active, not recruiting | Drug: 40 mg/day vormatrogine for 12 weeks, 30 mg/day vormatrogine for 12 weeks, 20 mg/day vormatrogine for 12 weeks, Placebo | Focal Epilepsy | 300 | 2026-01-29 | Jan 2027 | ≤ 164 d | 2026-08-03 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood EpilepsyNCT04015141Proportion of 50% Responders For All Seizures During the Maintenance Period of Core Study | Phase 2 | Active, not recruiting | Drug: Perampanel Oral Suspension, Perampanel Tablet | Pediatric Epileptic Syndrome, Partial-onset Seizures | 100 | 2019-05-31 | 2027-04-06 | in 229 d | 2026-07-10 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study to Evaluate the Safety of Fycompa Injection in Participants With Partial-Onset Seizures or Primary Generalized Tonic- Clonic SeizuresNCT06657378observationalNumber of Participants with Adverse Drug Reactions (ADRs) and Adverse Events (AEs) | — | Recruiting | Other: No Intervention | Partial-Onset Seizures, Primary Generalized Tonic-clonic Seizures | 110 | 2024-11-18 | 2028-06-15 | in 665 d | 2026-07-01 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Long-Term Follow-Up of a Cohort of Participants Prescribed Epidyolex in France in a Real-life SettingNCT05772429observationalRetention Rate Percentage After Initiation of Treatment With Epidyolex | — | Active, not recruiting | Drug: Epidiolex | Seizures | 158 | 2023-04-17 | Jul 2026 | — | 2026-06-15 |
| NPCE | NeuroPace | $490M | RNS System NAUTILUS StudyNCT0514757112-week post-operative serious device-related adverse event (SADE) rate | Not applicable | Completed | Device: Responsive stimulation, Sham stimulation | Epilepsy, Idiopathic Generalized Epilepsy, Generalized Tonic Clonic Seizure | 100 | 2022-08-09 | 2025-04-04actual | — | 2026-06-08 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset SeizuresNCT06798896Percent change (PCH) from baseline in focal onset seizure frequency per 28 days over the Maintenance Period | Phase 2 | Recruiting | Drug: SPN-817, Placebo | Focal Onset Seizures | 216 | 2024-12-30 | Aug 2027 | ≤ 376 d | 2026-06-01 |
| NBIX | Neurocrine Biosciences | $15.7B | Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEENCT05226780Number of Participants with Serious treatment-emergent adverse events (TEAEs), TEAEs Leading to Discontinuation and Fatal TEAEs | Phase 2 | Terminatedsponsor's stated reason: This study was prematurely terminated due to sponsor decision. | Drug: NBI-921352 | SCN8A Developmental and Epileptic Encephalopathy Syndrome | 8 | 2022-07-12 | 2025-11-12actual | — | 2026-05-27 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset SeizuresNCT05614063Median percent change (MPC) in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo. | Phase 3 | Completed | Drug: XEN1101, Placebo | Focal Onset Seizures | 380 | 2022-11-18 | 2026-01-12actual | — | 2026-05-14 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3)NCT05716100Median percent change (MPC) in focal seizure frequency from baseline to DBP for XEN1101 versus placebo. | Phase 3 | Recruiting | Drug: XEN1101, Placebo | Focal Onset Seizures | 360 | 2023-05-09 | Oct 2026 | ≤ 72 d | 2026-05-14 |
| SNY | Sanofi | — | A Study of the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi ArabiaNCT06714448observationalPercentage of healthcare professionals who received and read the educational materials | — | Completed | Drug: Sodium valporate | Epilepsy, Seizures | 455 | 2025-04-29 | 2025-09-22actual | — | 2026-04-28 |
| NMTC | NeuroOne Medical Technologies Corporation | $75M | Post-Market Real-World Evidence Registry for the NeuroOne OneRF® Ablation System for EpilepsyNCT07546253observationalEvaluate seizure outcomes | — | Not yet recruiting | Other: Participants are not assigned an intervention as part of the study. | Drug Resistant Epilepsy, Refractory Epilepsy | 100 | Jul 2026 | Jul 2028 | ≤ 711 d | 2026-04-22 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant EpilepsyNCT05518578Effects of SPN-817 on safety and tolerability | Phase 2 | Recruiting | Drug: SPN-817 | Epilepsy, Seizures, Epileptic | 60 | 2023-02-07 | 2027-12-31 | in 498 d | 2026-04-21 |
| NPCE | NeuroPace | $490M | RNS® System Epilepsy Post-Approval StudyNCT02403843observationalSAE rate | — | Completed | Device: RNS System | Epilepsy | 345 | Jun 2015 | Dec 2023actual | — | 2026-04-09 |
| PTCT | PTC Therapeutics | $6.1B | A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory EpilepsyNCT04378075results2026-03-25Percent Change From Baseline to Week 24 in the Number of Observable Motor Seizures Per 28 Days During the Double-blind Period | Phase 2/3 | Terminatedsponsor's stated reason: Sponsor decision. | Drug: Vatiquinone · Other: Placebo | Mitochondrial Diseases, Drug Resistant Epilepsy, Leigh Disease, Leigh Syndrome, Mitochondrial Encephalopathy (MELAS), Pontocerebellar Hypoplasia Type 6 (PCH6), Alpers Disease, Alpers Syndrome | 68 | 2020-09-28 | 2023-03-18actual | — | 2026-03-31 |
| LIVN | LivaNova | $4.4B | Non-interventional Study Describing Healthcare Resource Utilisation and Clinical Outcomes Associated With VNS Therapy in UK.NCT04779814observationalChange in hospital resource utilization | — | Terminatedsponsor's stated reason: The study was terminated by the sponsor due to persistent delays in recruitment and data availability, including access to the healthcare resource utilization database, which made it difficult to generate meaningful outcomes. | — | Epilepsy | 97 | 2021-05-11 | 2025-08-19actual | — | 2026-03-25 |
| NBIX | Neurocrine Biosciences | $15.7B | Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepNCT05301894results2026-02-13The Number of Participants With Serious Treatment-emergent Adverse Events (TEAEs) | Phase 2 | Terminatedsponsor's stated reason: Business decision | Drug: NBI-827104 | Epileptic Encephalopathy, Continuous Spike and Wave During Sleep | 19 | 2022-06-07 | 2025-01-27actual | — | 2026-02-13 |
| RAPP | Rapport Therapeutics Inc. | $2.4B | Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal EpilepsyNCT06377930Change in long episode frequency during the treatment period compared to pre-treatment baseline: Responder proportion, Percent Change Percent change | Phase 2 | Completed | Drug: RAP-219 | Focal Onset Seizures | 30 | 2024-10-10 | 2025-09-26actual | — | 2026-02-05 |
| RAPP | Rapport Therapeutics Inc. | $2.4B | A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset SeizuresNCT07219407Incidence of treatment-emergent adverse events (TEAEs) | Phase 2 | Recruiting | Drug: RAP-219 | Focal Epilepsy, Epilepsy, Refractory Focal Epilepsy, Seizure, Focal Seizure, Focal Onset Seizure | 30 | 2025-12-15 | 2028-02-03 | in 532 d | 2026-01-23 |
| NPCE | NeuroPace | $490M | RNS System LGS Feasibility StudyNCT05339126Safety: Annual device-related serious adverse event (SADE) rate | Phase 2 | Active, not recruiting | Device: RNS System | Epilepsy, Lennox Gastaut Syndrome, Lennox-Gastaut Syndrome, Intractable, Seizures, Seizures, Generalized | 24 | 2022-10-04 | 2026-05-31 | — | 2026-01-12 |
| ABBV | AbbVie | $457.5B | An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset SeizuresNCT04686786results2025-12-11Number of Participants With Treatment Emergent Adverse Event (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) | Phase 2 | Terminatedsponsor's stated reason: Closed early after CVL-865-SZ-001 (NCT04244175) did not meet its primary objective | Drug: CVL-865 | Seizures | 105 | 2020-12-08 | 2024-12-05actual | — | 2025-12-11 |
| NBIX | Neurocrine Biosciences | $15.7B | Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)NCT04873869results2025-10-16Percentage Change From Baseline in 28-day Seizure Frequency for Countable Motor Seizures During the 16-week Treatment Period | Phase 2 | Terminatedsponsor's stated reason: This study was prematurely terminated due to sponsor decision. | Drug: NBI-921352, Placebo | SCN8A Developmental and Epileptic Encephalopathy Syndrome | 8 | 2022-01-31 | 2023-03-17actual | — | 2025-10-16 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | A Study With SAGE-547 for Super-Refractory Status EpilepticusNCT02477618results2019-05-02Number of Participants Able to be Weaned Off All Third-Line Agents Prior to End of Double-Blind SAGE-547 or Placebo Infusion, and Remain Off All Third-Line Agents for ≥ 24 Hours Following the End of SAGE-547 or Placebo Infusion | Phase 3 | Completed | Drug: SAGE-547, Placebo | Super-Refractory Status Epilepticus | 132 | Jun 2015 | 2017-07-18actual | — | 2025-10-14 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | SPN-817 Open-Label Extension Study in Adults With Focal Onset SeizuresNCT07141329Incidence of treatment-emergent adverse events | Phase 2 | Recruiting | Drug: SPN-817 | Focal Onset Seizures | 100 | 2025-07-30 | 2027-12-31 | in 498 d | 2025-10-10 |
| 4523.T | Eisai Inc. | $8.7B | A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet SyndromeNCT04572243results2025-10-08Core Study: Percent Change From Baseline in Convulsive Seizure Frequency Per 28 Days During the Treatment Period | Phase 3 | Terminatedsponsor's stated reason: The study was terminated by Sponsor and the decision was not due to any safety or efficacy reasons. | Drug: Placebo, Lorcaserin | Epilepsies, Myoclonic | 22 | 2020-09-23 | 2024-08-15actual | — | 2025-10-08 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status EpilepticusNCT02052739results2022-05-03Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Phase 1/2 | Completed | Drug: SAGE-547 | Super-refractory Status Epilepticus | 25 | 2014-03-21 | 2015-05-03actual | — | 2025-09-15 |
| SUPN | Supernus Pharmaceuticals, Inc. | $2.8B | An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status EpilepticusNCT02433314expanded access | — | No longer available | Drug: SAGE-547 | Super-Refractory Status Epilepticus | — | — | — | — | 2025-09-15 |
| NBIX | Neurocrine Biosciences | $15.7B | Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-827104 in Pediatric Subjects With Epileptic Encephalopathy With Continuous Spike-and-Wave During SleepNCT04625101results2025-09-05Ratio of Spike-Wave Index (SWI) During First Hour of Nonrapid Eye Movement (NREM) Sleep at Week 6 | Phase 2 | Completed | Drug: NBI-827104, Placebo | Epileptic Encephalopathy, Continuous Spike and Wave During Sleep | 24 | 2021-04-26 | 2022-08-08actual | — | 2025-09-05 |
| ABBV | AbbVie | $457.5B | A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset SeizuresNCT04244175results2025-05-30Response Ratio (RRatio) | Phase 2 | Completed | Drug: Placebo, CVL-865 | Seizures | 154 | 2020-01-27 | 2024-05-21actual | — | 2025-05-30 |
| NPCE | NeuroPace | $490M | RNS System RESPONSE StudyNCT04839601Short-term chronic serious adverse device effect (SADE) rate | Not applicable | Terminatedsponsor's stated reason: Inadequate Enrollment | Device: RNS System | Epilepsy, Partial Seizure, Neurostimulator; Complications, Drug Resistant Epilepsy, Focal Epilepsy | 9 | 2021-10-27 | 2025-05-01actual | — | 2025-05-22 |
| PRAX | Praxis Precision Medicines | $10.3B | An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic SeizuresNCT06908356To evaluate the efficacy of PRAX-628 on seizure frequency in adults with FOS or PGTCS currently taking ASMs | Phase 2 | Recruiting | Drug: 30mg PRAX-628 | Focal Onset Seizure, Primary Generalized Epilepsy | 50 | 2025-01-10 | Jul 2025 | — | 2025-04-03 |
| PFE | Pfizer | $155.3B | LORA-PITA IV General InvestigationNCT03905798results2025-03-10observationalNumber of the Participants With Adverse Drug Reactions | — | Completed | Drug: Lorazepam | Status Epilepticus | 206 | 2019-11-18 | 2023-11-15actual | — | 2025-03-10 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEENCT04912856results2025-02-14Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) Related to Intervention | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision; not a safety decision | Drug: XEN496 | Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes | 8 | 2021-08-17 | 2023-11-17actual | — | 2025-02-14 |
| 4523.T | Eisai Inc. | $8.7B | Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory EpilepsiesNCT04457687expanded access | — | Available | Drug: Lorcaserin | Epilepsies, Myoclonic, Drug Resistant Epilepsy | — | — | — | — | 2025-01-30 |
| LIVN | LivaNova | $4.4B | IMPACT of AspireSR® for VNS Therapy on Healthcare Resource Utilisation and Clinical Outcomes.NCT05975931observationalDescriptive comparison of healthcare resource use (HCRU) | — | Terminatedsponsor's stated reason: The decision to terminate was taken based on study team capacity not sufficient and alignment with the sponsor. | — | Epilepsy | 15 | 2022-01-20 | 2024-01-30actual | — | 2024-12-03 |
| LIVN | LivaNova | $4.4B | Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.NCT03529045observationalSeizure Frequency | — | Completed | Device: Vagus Nerve Stimulation (VNS) Therapy | Epilepsy, Seizures, Drug Resistant Epilepsy | 827 | 2018-02-05 | 2024-09-11actual | — | 2024-11-22 |
| NBIX | Neurocrine Biosciences | $15.7B | A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset SeizuresNCT05159908Number of Participants with Serious Treatment-emergent Adverse Events (TEAEs), TEAEs Leading to Discontinuation of Study Treatment, and Fatal TEAEs | Phase 2 | Completed | Drug: NBI-921352, Placebo | Focal Onset Seizure, Focal Onset Epilepsy | 101 | 2021-11-08 | 2023-08-21actual | — | 2024-09-26 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal EpilepsyNCT03796962results2024-09-24Median Percent Change in Focal Seizure Frequency | Phase 2 | Active, not recruiting | Drug: XEN1101 | Focal Epilepsy | 325 | 2019-01-30 | 2021-09-02actual | — | 2024-09-24 |
| XENE | Xenon Pharmaceuticals Inc. | $6.1B | XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic EncephalopathyNCT04639310results2024-08-23Percent Change From Baseline in Monthly (28 Day) Countable Motor Seizure Frequency During the Blinded Treatment Period | Phase 3 | Terminatedsponsor's stated reason: Sponsor decision; Not a safety decision | Drug: XEN496, Placebo | Epilepsy, Epilepsy in Children, Epilepsy; Seizure, Disease, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Epileptic Syndromes | 8 | 2021-03-29 | 2023-05-16actual | — | 2024-08-23 |
| NBIX | Neurocrine Biosciences | $15.7B | Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset SeizuresNCT05493293The occurrence of serious treatment-emergent adverse events (TEAEs) | Phase 2 | Terminatedsponsor's stated reason: The long-term extension study was terminated because the parent study NBI-921352-FOS2021 (NCT05159908) failed to meet its primary endpoint. | Drug: NBI-921352 | Focal Onset Seizure, Focal Onset Epilepsy | 82 | 2022-11-09 | 2024-03-11actual | — | 2024-04-12 |
| 4523.T | Eisai Inc. | $8.7B | Pharmacokinetic Study With an Oral Suspension of Perampanel as Adjunctive Therapy in Pediatric Subjects With EpilepsyNCT02914314results2023-09-15Dose Normalized Area Under the Concentration-Time Curve for Dosing Interval at Steady State (AUCtau,ss) of Perampanel During the Maintenance Period of the Core Phase for Non-EIAED Participants | Phase 2 | Completed | Drug: perampanel | Epilepsy | 26 | 2017-02-20 | 2022-08-23actual | — | 2024-03-15 |
| GAIA | Gaia AG | $36M | Formative Validation of the MoveChecker SystemNCT05824611observationalmotion sequences of at least 60 epileptic seizures | — | Completed | Other: collect movement data from epileptic seizures | Epilepsy | 53 | 2023-02-27 | 2023-12-31actual | — | 2024-02-09 |
| PRAX | Praxis Precision Medicines | $10.3B | A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic EncephalopathyNCT05407727observationalAssess disease burden and any variation in disease progression over time, as reflected by electrographic seizures, interictal epileptiform discharges (IEDs), and spectral features, as measured on at-home video electroencephalograms (vEEGs) | — | Completed | — | SCN2A-DEE, Epilepsy | 5 | 2022-04-15 | 2023-03-31actual | — | 2024-01-10 |
| 4523.T | Eisai Inc. | $8.7B | A Post-marketing Observational Study Of The Use Of Zonisamide (ZNS) in the Adjunctive Treatment Of Adult Patients With Partial Onset Seizures (Study E2090-E044-410) (ZOOM)NCT01830868observationalRetention Rate of Zonisamide (ZNS) after 6 months from Baseline | — | Completed | Drug: Zonisamide tablets | Partial Onset Seizures | 104 | Mar 2012 | Jun 2013actual | — | 2023-06-18 |
| 4523.T | Eisai Limited | $8.7B | A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized EpilepsyNCT04252846observationalRetention Rate at Month 12 | — | Completed | Drug: Perampanel | Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures | 191 | 2020-07-20 | 2023-01-12actual | — | 2023-02-09 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of the Safety and Tolerability of GWP42006 in Healthy SubjectsNCT01918735The incidence of adverse events as measure of subject safety | Phase 1 | Completed | Drug: Placebo, GWP42006 | Epilepsy | 66 | Aug 2013 | Dec 2013actual | — | 2022-12-20 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of GWP42006 in People With Focal Seizures - Part BNCT02365610Percentage change from baseline to the end of treatment in focal seizure frequency in subjects taking GWP42006 compared to placebo. | Phase 2 | Completed | Drug: GWP42006, Placebo Control | Epilepsy, Focal Seizures | 162 | Mar 2016 | Jul 2017actual | — | 2022-12-20 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of GWP42006 in People With Focal Seizures - Part ANCT02369471Pharmacokinetic parameters of GWP42006 and metabolites: Cmax, Cmin, tmax, AUC(0-t), AUC(0-inf) and t1/2, in the presence of other AEDs. | Phase 2 | Completed | Drug: GWP42006, Placebo | Epilepsy, Focal Seizures | 32 | Mar 2015 | Oct 2015actual | — | 2022-12-20 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With EpilepsyNCT02607891Maximum plasma concentration (Cmax) of STP, VPA, cannabidiol (CBD). | Phase 2 | Completed | Drug: GWP42003-P, Placebo | Epilepsy | 35 | 2016-11-09 | 2018-09-11actual | — | 2022-12-20 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With EpilepsyNCT02607904Number of participants who experienced an adverse event. | Phase 2 | Completed | Drug: GWP42003-P | Epilepsy | 30 | 2016-12-15 | 2019-05-27actual | — | 2022-12-20 |
| HLUN-B.CO | H. Lundbeck A/S | — | A Study of Lu AG06466 in Participants With Treatment Resistant Focal EpilepsyNCT05081518Number of "Long Episodes" (Electrocorticographic [ECoG] Seizures) | Phase 1 | Terminatedsponsor's stated reason: The study was terminated due to enrolment challenges | Drug: Lu AG06466, Placebo | Focal Epilepsy | 1 | 2021-09-29 | 2022-04-14actual | — | 2022-11-09 |
| LIVN | LivaNova | $4.4B | Microburst Vagus Nerve Stimulator (VNS) Therapy Feasibility StudyNCT03446664Efficacy Primary Endpoint: Percent change from baseline in seizure frequency | Not applicable | Completed | Device: Microburst Stimulation | Epilepsies, Partial, Epilepsy, Tonic-Clonic | 33 | 2018-02-27 | 2021-07-30actual | — | 2022-10-25 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)NCT02091206results2018-07-19Number Of Participants Who Experienced Severe Treatment-Emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: GWP42003-P 5 mg/kg/day Dose, Placebo control, GWP42003-P 10 mg/kg/day Dose, GWP42003-P 20 mg/kg/day Dose | Epilepsy, Dravet Syndrome | 34 | 2014-10-22 | 2015-03-09actual | — | 2022-09-28 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)NCT02091375results2018-07-20Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period | Phase 3 | Completed | Drug: GWP42003-P 20 mg/kg/day Dose, Placebo control | Epilepsy, Dravet Syndrome | 120 | 2015-03-30 | 2015-11-26actual | — | 2022-09-28 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and AdultsNCT02224560results2018-07-27Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period | Phase 3 | Completed | Drug: GWP42003-P, Placebo control | Epilepsy, Lennox Gastaut Syndrome | 225 | 2015-06-08 | 2016-05-19actual | — | 2022-09-28 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and AdultsNCT02224690results2018-07-27Percentage Change From Baseline In Drop Seizure Frequency During The Treatment Period | Phase 3 | Completed | Drug: GWP42003-P 20 mg/kg/day Dose, Placebo | Epilepsy, Lennox-Gastaut Syndrome | 171 | 2015-04-28 | 2016-03-18actual | — | 2022-09-28 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet SyndromeNCT02224703results2019-08-01Change In Convulsive Seizures During The Treatment Period Compared To Baseline | Phase 3 | Completed | Drug: GWP42003-P, Placebo Control | Epilepsy, Dravet Syndrome | 199 | 2015-04-13 | 2018-04-09actual | — | 2022-09-28 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)NCT02544763results2020-09-23Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) | Phase 3 | Completed | Drug: GWP42003-P, Placebo | Tuberous Sclerosis Complex, Seizures | 224 | 2016-04-06 | 2019-01-22actual | — | 2022-09-28 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and CannabidiolNCT02564952results2018-09-11Number Of Participants Who Experienced Severe OLE-Emergent AEs | Phase 2 | Completed | Drug: GWP42003-P, Clobazam | Epilepsy | 18 | 2016-03-11 | 2017-06-07actual | — | 2022-09-28 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and CannabidiolNCT02565108results2018-08-23Pharmacokinetics (PK): Maximum Measured Plasma Concentration (Cmax) Of CLB And N-CLB With GWP42003-P Treatment, Days 1 And 33 | Phase 2 | Completed | Drug: GWP42003-P 20 mg/kg/Day Dose, Placebo, Clobazam | Epilepsy | 20 | 2016-01-20 | 2016-07-21actual | — | 2022-09-28 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | CX-8998 for Absence SeizuresNCT03406702results2022-09-08Change From Baseline to End of Treatment in QT Interval Corrected for Heart Rate Using Fridericia's Formula (QTcF) | Phase 2 | Completed | Drug: CX-8998 | Epilepsy | 7 | 2018-02-25 | 2019-03-29actual | — | 2022-09-08 |
| 4523.T | Eisai Co., Ltd. | $8.7B | Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic SeizuresNCT03059381observationalNumber of participants with any serious adverse event | — | Completed | Drug: Fycompa | Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures | 519 | 2016-08-01 | 2021-03-21actual | — | 2022-08-05 |
| JAZZ | Jazz Pharmaceuticals | $16.4B | An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)NCT02544750results2022-07-14Number of Participants With Any Treatment-emergent Adverse Events, Discontinuations Due to AEs, Serious AEs, and Treatment-related AEs (TEAE) | Phase 3 | Completed | Drug: GWP42003-P | Tuberous Sclerosis Complex, Seizures | 199 | 2016-08-31 | 2021-06-11actual | — | 2022-07-14 |
| 4523.T | Eisai Inc. | $8.7B | Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic SeizuresNCT03288129results2022-05-16Percentage of Participants Remaining on Perampanel Treatment at 3 Months After the Initiation of Treatment | Phase 4 | Completed | Drug: Perampanel | Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures | 54 | 2017-08-23 | 2021-04-27actual | — | 2022-05-16 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Evaluate the Pharmacodynamic Activity of E2730 in Adult Participants With Photosensitive EpilepsyNCT03603639results2022-05-04Mean Change From Baseline in the Standard Photosensitivity Response (SPR) in the Most Sensitive Eye Condition at 8 Hours Post-dose on Day 1 of Each Treatment Period | Phase 2 | Terminatedsponsor's stated reason: The study was stopped due to efficacy reasons. | Drug: Placebo, E2730 | Photosensitive Epilepsy | 6 | 2018-07-27 | 2019-02-14actual | — | 2022-05-04 |
| SNY | Sanofi | — | Study of Excretion Balance and Pharmacokinetics of [14C]-Sodium Valproate (3.7 MBq) in Healthy Postmenopausal or Permanently Sterile Female SubjectsNCT03681158Percentage of radioactive dose excreted in urine and feces | Phase 1 | Completed | Drug: sodium valproate | Epilepsy | 5 | 2018-10-05 | 2019-04-11actual | — | 2022-04-25 |
| 4523.T | Eisai Co., Ltd. | $8.7B | Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic SeizuresNCT03059329observationalNumber of participants with any serious adverse event | — | Completed | Drug: Fycompa | Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures | 3,809 | 2016-08-01 | 2019-09-13actual | — | 2022-03-02 |
| PFE | Pfizer | $155.3B | A Safety Study For Prevenar 13 Among Chinese ChildrenNCT03656939results2021-08-27observationalIncidence Rate (Per 1000 Person Days) of All Seizures Through 0 to 3 Days After Dose 1 | — | Completed | — | Seizures, Urticaria and Angioedema, Apnea, Fever | 21,240 | 2018-08-01 | 2020-07-31actual | — | 2021-08-27 |
| 4523.T | Eisai Co., Ltd. | $8.7B | Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)NCT03201900results2020-02-25Percentage of Participants With Partial-onset Seizures (POS) Who Achieved Seizure-free Status During the 26-week Maintenance Period of 4 mg Perampanel | Phase 3 | Completed | Drug: E2007 | Partial Onset Seizures | 91 | 2017-06-28 | 2019-02-28actual | — | 2021-08-05 |
| AQST | Aquestive Therapeutics | $542M | Safety and Tolerability Study of Diazepam Buccal Film (DBF) in Subjects With EpilepsyNCT03428360results2021-08-05Number of Subjects in the Safety Analysis Set With at Least 1 Treatment-emergent Adverse Event (TEAE) | Phase 3 | Completed | Drug: Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category | Epilepsy | 149 | 2018-01-23 | 2020-06-25actual | — | 2021-08-05 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Perampanel (E2007) Administered as an Adjunctive Therapy in Subjects With Refractory Partial-onset SeizuresNCT01618695results2020-06-05Core Phase: Percent Change in Seizure Frequency (For All Partial Seizures) Per 28 Days in the Randomization Phase Relative to Pre-randomization Phase (Baseline) | Phase 3 | Completed | Drug: Perampanel, Placebo | Partial-onset Seizures | 940 | 2012-05-15 | 2014-09-15actual | — | 2021-07-29 |
| 4523.T | Eisai Inc. | $8.7B | Rufinamide Given as Adjunctive Therapy in Participants With Refractory Partial SeizuresNCT00334958results2013-02-05Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase | Phase 3 | Completed | Drug: Placebo, Rufinamide | Epilepsy | 356 | 2006-02-13 | 2009-05-20actual | — | 2021-06-14 |
| AQST | Aquestive Therapeutics | $542M | Pharmacokinetics and Safety Study of Diazepam Buccal Film (DBF) in Pediatric Subjects With EpilepsyNCT03222349results2021-05-26Area Under the Concentration Time Curve (AUC) 0 to 4 Hours Post-dose | Phase 2 | Completed | Drug: Diazepam Buccal Film | Epilepsy | 24 | 2017-08-31 | 2020-01-28actual | — | 2021-05-26 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study of Intravenous Perampanel in Japanese Participants With EpilepsyNCT03754582results2021-01-05Number of Participants With Serious Adverse Events (SAEs) | Phase 2 | Completed | Drug: Perampanel, Perampanel | Epilepsy, Seizures | 21 | 2018-11-27 | 2019-12-10actual | — | 2021-01-05 |
| NVS | Novartis | — | Efficacy and Safety of BGG492 as Adjunctive Treatment in Patients With Partial Onset SeizuresNCT01147003To detect a dose-response by measuring the percent change in seizure frequency of BGG492 from baseline to maintenance period. | Phase 2 | Completed | Drug: Investigational new drug, company code: BGG492, Placebo, Investigational new drug, company code: BGG492 | Partial Onset Seizures | 93 | Jun 2010 | Sep 2011actual | — | 2020-12-17 |
| VRTX | Vertex Pharmaceuticals Incorporated | $133.9B | A Study to Evaluate the Efficacy and Safety of VX-765 in Subjects With Treatment-Resistant Partial EpilepsyNCT01501383Percent reduction in weekly seizure frequency during the Part A Late Treatment Period compared to the Part A Baseline Period | Phase 2 | Terminatedsponsor's stated reason: Terminated by Sponsor | Drug: VX-765 Part A, Placebo, VX-765 Part B | Epilepsy | 55 | Dec 2011 | Aug 2013actual | — | 2020-09-30 |
| 4523.T | Eisai Inc. | $8.7B | A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive EpilepsyNCT03686033results2020-09-28Mean Change From Baseline in the Photoparoxysmal Response (PPR) Range in the Most Sensitive Eye Condition at 8 Hours Postdose on Day 1 of Each Treatment Period | Phase 2 | Terminatedsponsor's stated reason: Safety Review | Drug: Placebo, E2082 | Photosensitive Epilepsy | 8 | 2018-10-31 | 2019-06-18actual | — | 2020-09-28 |
| AQST | Aquestive Therapeutics | $542M | Study of Diazepam Buccal Film Administered in the Interictal and in the Ictal-Periictal States to Adults With EpilepsyNCT03179891results2020-09-18Tmax Pharmacokinetic EndPoints | Phase 2 | Completed | Drug: Diazepam Buccal Film 12.5 mg | Epilepsy | 35 | 2017-05-25 | 2018-07-25actual | — | 2020-09-18 |
| LIVN | LivaNova | $4.4B | XLTCS - Accelerometer Data Collection in an Epilepsy Monitoring Unit (EMU)NCT04282681observationalEvaluate accelerometer data and tonic-clonic seizure data | — | Withdrawnsponsor's stated reason: Sponsor decision due to clinical strategy changes | Other: Accelerometer Live-Streaming Tool | Epilepsy, Tonic-Clonic | 0 | 2020-03-16 | 2021-08-28 | — | 2020-08-25 |
| AQST | Aquestive Therapeutics | $542M | Diazepam Buccal Film (DBF) - Diastat Rectal Gel (DRG) Crossover StudyNCT03953820results2020-08-18AUC 0-t | Phase 1/2 | Completed | Drug: Diazepam Buccal Film, Diastat® Rectal Gel (Valeant Pharmaceuticals USA) | Epilepsy | 31 | 2019-04-13 | 2019-07-31actual | — | 2020-08-18 |
| 4523.T | Eisai Inc. | $8.7B | An Extended Access Program for PerampanelNCT01871233expanded access | — | No longer available | Drug: Perampanel | Partial Onset Seizures | — | — | — | — | 2020-04-16 |
| 4523.T | Eisai Limited | $8.7B | A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal SeizuresNCT04257604observationalPercentage Change From Baseline in all Seizures Frequency at Month 6 | — | Completed | Drug: Perampanel | Partial Seizures | 243 | 2016-01-03 | 2019-04-30actual | — | 2020-02-06 |
| 4523.T | Eisai Co., Ltd. | $8.7B | A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With EpilepsyNCT04230044observationalNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESI) | — | Completed | Drug: Perampanel | Epilepsy, Partial-onset Seizures | 117 | 2016-04-11 | 2017-07-03actual | — | 2020-01-18 |
| 4523.T | Eisai Inc. | $8.7B | Evaluating the Efficacy and Safety of E2007 (Perampanel) Given as Adjunctive Therapy in Subjects With Refractory Partial SeizuresNCT00699972results2013-02-05Percent Change in the 28-day Seizure Frequency From Baseline to the End of the Double-blind Phase (Titration and Maintenance Phases) | Phase 3 | Completed | Drug: E2007 (perampanel), E2007 (perampanel), Placebo | Refractory Partial Seizures | 390 | 2008-04-30 | 2010-10-19actual | — | 2020-01-10 |
| CBLL | Ceribell Inc. | $929M | Does Use of Rapid Response EEG Impact Clinical Decision MakingNCT03534258observationalChange in physicians' diagnosis decision | — | Completed | Device: Ceribell Rapid Response EEG, Survey | Nonconvulsive Status Epilepticus, Seizures | 164 | 2018-04-30 | 2019-04-30actual | — | 2019-08-20 |
| GAIA | Gaia AG | $36M | Evaluating a Novel Internet Intervention for Persons With Epilepsy and DepressionNCT02791724Severity of depressive symptoms, measured by Patient Health Questionnaire - 9 items (PHQ-9) | Not applicable | Completed | Behavioral: Desiconnect · Other: CAU | Depression, Epilepsy | 200 | Jun 2016 | Feb 2018actual | — | 2019-08-02 |
| NPCE | NeuroPace | $490M | RNS® System LTT StudyNCT00572195results2019-06-26Number of Participants With Serious Adverse Events (SAE) | Phase 4 | Completed | Device: RNS® System | Epilepsy | 230 | Apr 2006 | May 2018actual | — | 2019-06-26 |
| 4523.T | Eisai Inc. | $8.7B | A Study With an Open-label Extension Phase to Evaluate the Effect of Perampanel (E2007) on Cognition, Growth, Safety, Tolerability, and Pharmacokinetics in AdolescentsNCT01161524results2019-05-15Change From Baseline to Week 19 in Cognition Drug Research (CDR) System Global Cognition Score (Core Study) | Phase 2 | Completed | Drug: Perampanel, Placebo | Epilepsy | 133 | Sep 2010 | Jun 2013actual | — | 2019-05-15 |
| ECOR | ElectroCore INC | $93M | Neurostimulation to the Vagus Nerve for the Reduction in Frequency of Seizures Associated With EpilepsyNCT01910129results2019-04-23Frequency of Seizures | Not applicable | Terminatedsponsor's stated reason: Slow enrollment | Device: gammaCore | Seizure | 13 | Jul 2013 | Jul 2014actual | — | 2019-04-23 |
| 4523.T | Eisai Inc. | $8.7B | Study to Investigate Dosage, Efficacy, and Safety of Fycompa in Routine Clinical Care of Patients With EpilepsyNCT03208660observationalPercentage of participants remaining on Fycompa treatment at specified time points after initiation of treatment (Retention rate) | — | Completed | Drug: Fycompa | Epilepsy | 2,000 | 2017-04-07 | 2019-03-15actual | — | 2019-04-11 |
| PFE | Pfizer | $155.3B | Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in JapanNCT02239380results2019-02-18Percentage of Participants Who Achieved Seizure Free Interval of At Least 30 Minutes After Initial Dose (Dose 1) of Study Drug | Phase 3 | Completed | Drug: Lorazepam | Status Epilepticus | 26 | Nov 2014 | Aug 2016actual | — | 2019-02-18 |
| 4523.T | Eisai Co., Ltd. | $8.7B | Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With EpilepsyNCT03780907Number of participants with Treatment Emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: E2007, E2007, Placebo | Epilepsy | 18 | 2003-02-14 | 2003-08-06actual | — | 2018-12-19 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Epilepsy and Seizure Disorders is matched — 34 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Epilepsy
- Seizures
- Focal Epilepsy
- Partial Onset Seizures
- Epilepsies, Partial
- Drug Resistant Epilepsy
- Focal Onset Seizures
- Focal Seizure
- Refractory Partial Seizures
- Epilepsy, Complex Partial
- Focal Onset Seizure
- Partial Seizures
- Seizure Disorder, Partial
- Epilepsy, Tonic-Clonic
- Epileptic Encephalopathy
- Focal Seizures
- Partial-onset Seizures
- Primary Generalized Tonic-Clonic Seizures
- Seizure
- Epilepsies, Myoclonic
- Epilepsy in Children
- Epilepsy, Partial
- Epilepsy, Partial Seizures
- Epilepsy; Seizure
- Epileptic Syndromes
- Focal Onset Epilepsy
- Idiopathic Generalized Epilepsy
- Partial Epilepsy
- Partial Onset Epilepsy
- Partial Seizures (With or Without Secondary Generalized Seizures)
- Photosensitive Epilepsy
- SCN8A Developmental and Epileptic Encephalopathy Syndrome
- Status Epilepticus
- Super-Refractory Status Epilepticus
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Epilepsy and Seizure Disorders” (a text search, wider than this page)